Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.31 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.31 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301785 | 0.85 | CNR2 (0.31) | TP53TSHRCNR1CNR2 | |
| SCHEMBL3298055 | 0.83 | PPARA (0.39) | TSHRCNR1CNR2 | |
| SCHEMBL3296586 | 0.80 | CNR2 (0.33) | S1PR1S1PR4S1PR3S1PR5TP53 | |
| SCHEMBL3294266 | 0.80 | CNR2 (0.34) | CNR1CNR2 | |
| SCHEMBL9345890 | 0.79 | CNR2 (0.35) | S1PR1S1PR4S1PR3S1PR5NR5A1 | |
| SCHEMBL3299249 | 0.79 | KDM4E (0.32) | S1PR1S1PR4S1PR3S1PR5TP53 | |
| SCHEMBL1454452 | 0.79 | LTA4H (0.46) | LTA4HCNR1CNR2 | |
| SCHEMBL3299388 | 0.78 | CNR2 (0.50) | CNR1CNR2 | |
| SCHEMBL5353479 | 0.78 | TP53 (0.36) | S1PR1S1PR4S1PR3S1PR5TP53 | |
| SCHEMBL5495925 | 0.78 | TP53 (0.58) | TP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741393-B2 | Organic silicon-based compound and method of producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | ARSA, OR10J3, HDAC10 | S1PR1 338/4885S1PR4 584/4885S1PR3 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.